Amplia Therapeutics
Amplia Therapeutics Limited focuses on developing therapies targeting focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company is positioned within the biotechnology sector, leveraging advanced scientific research to develop clinical candidates aimed at unmet medical needs, potentially offering transformative therapies in oncology and fibrotic diseases.
Short position
Amplia Therapeutics (ASX:ATX) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 30,144 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in November 2024. ATX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Amplia Therapeutics (ATX) company profile
Profile, insiders and operations
Company
AI-generated research profile of Amplia Therapeutics
ATX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links